Share this article Share this article MUMBAI, India and BALTIMORE, Feb. 1, 2021 /PRNewswire/ -- Lupin Pharmaceuticals Inc. (Lupin), global pharmaceutical company, announced today a partnership with Phil, Inc., which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among adult women. This treatment is designed to deliver a full course of therapy in...